Uncertainty and innovation

Understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments

Rosario Isasi, Vasiliki Rahimzadeh, Kathleen Charlebois

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The purpose of this qualitative study is to elucidate stakeholder perceptions of, and institutional practices related to cell-based therapies and products (CTP) regulation and commercialization in Canada. The development of reproducible, safe and effective CTPs is predicated on regulatory and commercialization environments that enable innovation. Manufacturing processes constitute a critical step for CTP development in this regard. The road from CTP manufacturing to translation in the clinic, however, has yet to be paved. This study aims to fill an empirical gap in the literature by exploring how CTP manufacturing facilities navigate Canadian regulatory and commercialization environments, which together drive the translation of novel CTPs from bench to bedside. Using the multi-level model of practice-driven institutional change proposed by Smets et al., we demonstrate how CTP manufacturing practices are governed by established standards, yet meaningfully shape higher-order regulatory and commercial norms in CTP research and development. We identify four key themes that undergird such processes of innovation: 1) managing regulatory uncertainty, which stems from an inability to classify CTPs within existing regulatory categories for approval and commercialization purposes; 2) building a ‘business case’ whereby a CTP's market potential is determined in large part by proving its safety and effectiveness; 3) standardizing manufacturing procedures that mobilize CTPs from a research and development phase to a commercialization one; and 4) networking between researchers and regulators to develop responsible commercialization processes that reflect the uniqueness of CTPs as distinct from other biologics and medical devices.

Original languageEnglish (US)
Pages (from-to)27-39
Number of pages13
JournalApplied and Translational Genomics
Volume11
DOIs
StatePublished - Dec 1 2016
Externally publishedYes

Fingerprint

Cytidine Triphosphate
Cell- and Tissue-Based Therapy
Uncertainty
Institutional Practice
Biological Products
Research
Canada
Manufacturing and Industrial Facilities
Research Personnel
Safety
Equipment and Supplies

Keywords

  • Canada
  • Cell-based therapies
  • Commercialization
  • Institutional change
  • Regenerative medicine
  • Regulation

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Biology
  • Pharmaceutical Science

Cite this

Uncertainty and innovation : Understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments. / Isasi, Rosario; Rahimzadeh, Vasiliki; Charlebois, Kathleen.

In: Applied and Translational Genomics, Vol. 11, 01.12.2016, p. 27-39.

Research output: Contribution to journalArticle

@article{08dfb7cc14564d0c9604e271ece5f6c9,
title = "Uncertainty and innovation: Understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments",
abstract = "The purpose of this qualitative study is to elucidate stakeholder perceptions of, and institutional practices related to cell-based therapies and products (CTP) regulation and commercialization in Canada. The development of reproducible, safe and effective CTPs is predicated on regulatory and commercialization environments that enable innovation. Manufacturing processes constitute a critical step for CTP development in this regard. The road from CTP manufacturing to translation in the clinic, however, has yet to be paved. This study aims to fill an empirical gap in the literature by exploring how CTP manufacturing facilities navigate Canadian regulatory and commercialization environments, which together drive the translation of novel CTPs from bench to bedside. Using the multi-level model of practice-driven institutional change proposed by Smets et al., we demonstrate how CTP manufacturing practices are governed by established standards, yet meaningfully shape higher-order regulatory and commercial norms in CTP research and development. We identify four key themes that undergird such processes of innovation: 1) managing regulatory uncertainty, which stems from an inability to classify CTPs within existing regulatory categories for approval and commercialization purposes; 2) building a ‘business case’ whereby a CTP's market potential is determined in large part by proving its safety and effectiveness; 3) standardizing manufacturing procedures that mobilize CTPs from a research and development phase to a commercialization one; and 4) networking between researchers and regulators to develop responsible commercialization processes that reflect the uniqueness of CTPs as distinct from other biologics and medical devices.",
keywords = "Canada, Cell-based therapies, Commercialization, Institutional change, Regenerative medicine, Regulation",
author = "Rosario Isasi and Vasiliki Rahimzadeh and Kathleen Charlebois",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.atg.2016.11.001",
language = "English (US)",
volume = "11",
pages = "27--39",
journal = "Applied and Translational Genomics",
issn = "2212-0661",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Uncertainty and innovation

T2 - Understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments

AU - Isasi, Rosario

AU - Rahimzadeh, Vasiliki

AU - Charlebois, Kathleen

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The purpose of this qualitative study is to elucidate stakeholder perceptions of, and institutional practices related to cell-based therapies and products (CTP) regulation and commercialization in Canada. The development of reproducible, safe and effective CTPs is predicated on regulatory and commercialization environments that enable innovation. Manufacturing processes constitute a critical step for CTP development in this regard. The road from CTP manufacturing to translation in the clinic, however, has yet to be paved. This study aims to fill an empirical gap in the literature by exploring how CTP manufacturing facilities navigate Canadian regulatory and commercialization environments, which together drive the translation of novel CTPs from bench to bedside. Using the multi-level model of practice-driven institutional change proposed by Smets et al., we demonstrate how CTP manufacturing practices are governed by established standards, yet meaningfully shape higher-order regulatory and commercial norms in CTP research and development. We identify four key themes that undergird such processes of innovation: 1) managing regulatory uncertainty, which stems from an inability to classify CTPs within existing regulatory categories for approval and commercialization purposes; 2) building a ‘business case’ whereby a CTP's market potential is determined in large part by proving its safety and effectiveness; 3) standardizing manufacturing procedures that mobilize CTPs from a research and development phase to a commercialization one; and 4) networking between researchers and regulators to develop responsible commercialization processes that reflect the uniqueness of CTPs as distinct from other biologics and medical devices.

AB - The purpose of this qualitative study is to elucidate stakeholder perceptions of, and institutional practices related to cell-based therapies and products (CTP) regulation and commercialization in Canada. The development of reproducible, safe and effective CTPs is predicated on regulatory and commercialization environments that enable innovation. Manufacturing processes constitute a critical step for CTP development in this regard. The road from CTP manufacturing to translation in the clinic, however, has yet to be paved. This study aims to fill an empirical gap in the literature by exploring how CTP manufacturing facilities navigate Canadian regulatory and commercialization environments, which together drive the translation of novel CTPs from bench to bedside. Using the multi-level model of practice-driven institutional change proposed by Smets et al., we demonstrate how CTP manufacturing practices are governed by established standards, yet meaningfully shape higher-order regulatory and commercial norms in CTP research and development. We identify four key themes that undergird such processes of innovation: 1) managing regulatory uncertainty, which stems from an inability to classify CTPs within existing regulatory categories for approval and commercialization purposes; 2) building a ‘business case’ whereby a CTP's market potential is determined in large part by proving its safety and effectiveness; 3) standardizing manufacturing procedures that mobilize CTPs from a research and development phase to a commercialization one; and 4) networking between researchers and regulators to develop responsible commercialization processes that reflect the uniqueness of CTPs as distinct from other biologics and medical devices.

KW - Canada

KW - Cell-based therapies

KW - Commercialization

KW - Institutional change

KW - Regenerative medicine

KW - Regulation

UR - http://www.scopus.com/inward/record.url?scp=85006342011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006342011&partnerID=8YFLogxK

U2 - 10.1016/j.atg.2016.11.001

DO - 10.1016/j.atg.2016.11.001

M3 - Article

VL - 11

SP - 27

EP - 39

JO - Applied and Translational Genomics

JF - Applied and Translational Genomics

SN - 2212-0661

ER -